This industry-sponsored symposium took place during the European Association of Neurology (EAN) Congress held in Helsinki, Finland, 29 June−2 July, 2024.

The proportion of boys in the science stream decreased from 62% to 54% during the same period ... 52.1% are women. Unlike for science, the gender gap in the commerce and arts streams hasn’t registered ...

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with ...

Tony Tulathimutte, a master comedian, has produced an audacious, original and highly disturbing book that steers directly ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with ...

TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001)– For ...

DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...

Gary Hilderbrand has been teaching at Harvard Graduate School of Design since 1990 and is currently the Peter Louis Hornbeck ...

Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal ...